. Author manuscript; available in PMC: 2020 Oct 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):124–130. doi: 10.1097/QAI.0000000000002120

Table 1.

Baseline characteristics of study participants with multidrug-resistant tuberculosis (MDR-TB), by HIV status – KwaZulu-Natal, South Africa (N=200).

	Total Cohort (N=200)	HIV+ (n=144)	HIV− (n=56)	p-value
	n (%)	n (%)	n (%)	p-value
Demographics
Age (median, IQR)	33 (26-41)	34 (29-40)	27 (21-49)	0.069^*
Gender (Female)	126 (63)	100 (69)	26 (46)	0.002 ^†
Race: Black	198 (99)	144 (100)	54 (96)	0.077 ^‡
Previous History of TB Treatment	130 (65)	104 (72)	26 (46)	<0.001 ^†
Smoking History(current or ever use)	47 (24)	35 (24)	12 (21)	0.667 ^†
Alcohol History (current or ever use)	62 (31)	48 (33)	14 (25)	0.253 ^†
Household Member with TB	35 (18)	22 (15)	13 (23)	0.185 ^†
Healthcare Worker, past 12 months	13 (7)	7 (5)	6 (11)	0.197 ^‡
Mineworker, past 12 months	6 (3)	5 (3)	1 (2)	1.000 ^‡
Prison, past 12 months	5 (3)	4 (3)	1 (2)	1.000 ^‡
HIV Characteristics
On antiretroviral therapy (ART)		116 (81)
CD4 Count (Median (IQR)), n=139		215 (109-376)
Virologically Suppressed, Baseline, n=97		64 (66)

HIV: Human immunodeficiency virus

Wilcoxon exact test (2-sided p-value)

^†

Chi-square test

^‡

Fisher’s exact test (2-sided p-value)